.jpg?format=webp&width=780)
A study assessing clinician consensus on ataluren usage in nonsense mutation Duchenne muscular dystrophy (nmDMD) patients reveals strong agreement. Conducted via modified Delphi methodology, involving 1:1 interviews and consensus surveys among healthcare professionals, the research found consensus (>66%) on 41 out of 42 statements. Findings suggest early initiation of ataluren to delay disease progression and maintain ambulation. Results indicate significant alignment among clinicians, emphasizing the drug's potential in nmDMD treatment.
Like
Save
Share